Due to Fc fusion and specific uPA cleavage in the tumor site, Fc-U-ZHER2-MMAE showed an extended circulation half-life compared to ZHER2-MMAE (7.1 h, 59-fold longer) and had significantly enhanced accumulation at the tumor site compared to the conventional full-length antibody-coupled ADC Herceptin-MMAE. Here, PLAU is linked to neoplasm.